Abstract
Drug loaded hydrofluoroalkane (HFA) sprays can generate effective pharmaceutical formulations, but a deeper understanding of the manner in which these dynamic systems drive the process of in situ semi-solid dosage form assembly is required. The aim of this study was to investigate the effect of the
matrix assembly and composition on drug localisation in human skin. Comparing the characteristics of sprays constituting HFA 134a, ethanol (EtOH), poly(vinyl pyrrolidone) K90, isopropyl myristate (IPM), and poly(ethylene glycol) (PEG) demonstrated that the addition of non-volatile solvents acted to delay EtOH evaporation, control the degree of drug saturation (DS) and enhance the corticosteroid delivery from HFA spray formulations. In a dose matched skin penetration study the HFA sprays containing only EtOH as a co-solvent delivered 2.1 g BMV (DS 13.5) into the tissue, adding IPM to the EtOH HFA delivered
4.03 g BMV (DS 11.2), whist adding PEG to the EtOH HFA delivered 6.1 g BMV (DS 0.3). Compared to commercial cream (delivering 0.91 g BMV) the EtOH/PEG HFA spray deposited over 6 times (p < 0.05) more drug into the skin. Post spray deposition characterisation of the semi-solid suggested that the superior performance of the EtOH/PEG HFA spray was a consequence of retarding EtOH evaporation and presenting the drug in an EtOH rich PEG residual phase, which promoted BMV passage through the SC and into epidermis.
matrix assembly and composition on drug localisation in human skin. Comparing the characteristics of sprays constituting HFA 134a, ethanol (EtOH), poly(vinyl pyrrolidone) K90, isopropyl myristate (IPM), and poly(ethylene glycol) (PEG) demonstrated that the addition of non-volatile solvents acted to delay EtOH evaporation, control the degree of drug saturation (DS) and enhance the corticosteroid delivery from HFA spray formulations. In a dose matched skin penetration study the HFA sprays containing only EtOH as a co-solvent delivered 2.1 g BMV (DS 13.5) into the tissue, adding IPM to the EtOH HFA delivered
4.03 g BMV (DS 11.2), whist adding PEG to the EtOH HFA delivered 6.1 g BMV (DS 0.3). Compared to commercial cream (delivering 0.91 g BMV) the EtOH/PEG HFA spray deposited over 6 times (p < 0.05) more drug into the skin. Post spray deposition characterisation of the semi-solid suggested that the superior performance of the EtOH/PEG HFA spray was a consequence of retarding EtOH evaporation and presenting the drug in an EtOH rich PEG residual phase, which promoted BMV passage through the SC and into epidermis.
Original language | English |
---|---|
Pages (from-to) | 157-165 |
Number of pages | 9 |
Journal | International Journal of Pharmaceutics |
Volume | 452 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - 16 Aug 2013 |
Keywords
- Supersaturation; Volatile evaporation; HFA spray; Skin delivery; Corticosteroids